Literature DB >> 24792911

Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses.

Masashi Watanabe1, Kyung Duk Moon1, Melanie S Vacchio1, Karen S Hathcock1, Richard J Hodes2.   

Abstract

Antigen specificity is critical in immune response and requires integration of antigen-specific signals with antigen-nonspecific signals such as those provided by cytokines. The mechanism integrating these pathways is incompletely understood. We report here that antigen-specific proliferative responses of CD4(+) T cells required downmodulation of tumor suppressor p53. In the absence of T cell receptor (TCR) signal, IL-2 induced sustained increase in p53 protein, which prevented proliferative responses despite strong signaling through the IL-2 receptor. In contrast, TCR signaling resulted in early termination of p53 protein expression by decreasing p53 mRNA as well as strong transcriptional induction of the p53-regulating protein Mdm2. Downmodulation of p53 in response to antigen stimulation was in fact critical for antigen-specific T cell proliferation, and preventing p53 degradation by inhibiting Mdm2 resulted in sustained p53 protein and prevented antigen-specific T cell proliferation. It is thus termination of p53 by TCR signaling that allows proliferative responses, enforcing antigen specificity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792911      PMCID: PMC4073799          DOI: 10.1016/j.immuni.2014.04.006

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  39 in total

Review 1.  In vivo activation of antigen-specific CD4 T cells.

Authors:  M K Jenkins; A Khoruts; E Ingulli; D L Mueller; S J McSorley; R L Reinhardt; A Itano; K A Pape
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  The role of p53 in regulating antiviral T cell responses.

Authors:  J M Grayson; J G Lanier; J D Altman; R Ahmed
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 3.  P63 and P73: P53 mimics, menaces and more.

Authors:  A Yang; F McKeon
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

4.  Regulation of arthritis by p53: critical role of adaptive immunity.

Authors:  Egle Simelyte; Sanna Rosengren; David L Boyle; Maripat Corr; Douglas R Green; Gary S Firestein
Journal:  Arthritis Rheum       Date:  2005-06

5.  The basis for IL-2-induced IL-2 receptor alpha chain gene regulation: importance of two widely separated IL-2 response elements.

Authors:  H P Kim; J Kelly; W J Leonard
Journal:  Immunity       Date:  2001-07       Impact factor: 31.745

6.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.

Authors:  N E Sharpless; N Bardeesy; K H Lee; D Carrasco; D H Castrillon; A J Aguirre; E A Wu; J W Horner; R A DePinho
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

7.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.

Authors:  P Krimpenfort; K C Quon; W J Mooi; A Loonstra; A Berns
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

8.  Regulatory role of p53 in experimental autoimmune encephalomyelitis.

Authors:  Yoshinobu Okuda; Misa Okuda; Claude C A Bernard
Journal:  J Neuroimmunol       Date:  2003-02       Impact factor: 3.478

Review 9.  T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.

Authors:  Kathrin Warner; Nicole Weit; Giuliano Crispatzu; Joan Admirand; Dan Jones; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

10.  The basis for TCR-mediated regulation of the IL-2 receptor alpha chain gene: role of widely separated regulatory elements.

Authors:  Hyoung-Pyo Kim; Warren J Leonard
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

View more
  41 in total

1.  Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.

Authors:  Anusara Daenthanasanmak; Supinya Iamsawat; Paramita Chakraborty; Hung D Nguyen; David Bastian; Chen Liu; Shikhar Mehrotra; Xue-Zhong Yu
Journal:  Blood       Date:  2018-12-04       Impact factor: 22.113

2.  FOXO3-NF-κB RelA Protein Complexes Reduce Proinflammatory Cell Signaling and Function.

Authors:  Matthew G Thompson; Michelle Larson; Amy Vidrine; Kelly Barrios; Flor Navarro; Kaitlyn Meyers; Patricia Simms; Kushal Prajapati; Lennox Chitsike; Lance M Hellman; Brian M Baker; Stephanie K Watkins
Journal:  J Immunol       Date:  2015-11-11       Impact factor: 5.422

3.  Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

Authors:  Jonathan P McNally; Scott H Millen; Vandana Chaturvedi; Nora Lakes; Catherine E Terrell; Eileen E Elfers; Kaitlin R Carroll; Simon P Hogan; Paul R Andreassen; Julie Kanter; Carl E Allen; Michael M Henry; Jay N Greenberg; Stephan Ladisch; Michelle L Hermiston; Michael Joyce; David A Hildeman; Jonathan D Katz; Michael B Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

4.  A role for the histone H2A deubiquitinase MYSM1 in maintenance of CD8+ T cells.

Authors:  Michael Förster; Rupinder K Boora; Jessica C Petrov; Nassima Fodil; Isabella Albanese; Jamie Kim; Philippe Gros; Anastasia Nijnik
Journal:  Immunology       Date:  2017-02-20       Impact factor: 7.397

5.  T cell signalling: p53 controls the crowd.

Authors:  Kirsty Minton
Journal:  Nat Rev Immunol       Date:  2014-05-09       Impact factor: 53.106

6.  Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.

Authors:  Tania L Slatter; Michelle Wilson; Chingwen Tang; Hamish G Campbell; Vernon K Ward; Vivienne L Young; David Van Ly; Nicholas I Fleming; Antony W Braithwaite; Margaret A Baird
Journal:  Oncoimmunology       Date:  2015-12-17       Impact factor: 8.110

7.  Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.

Authors:  Matthew J Scheffel; Gina Scurti; Patricia Simms; Elizabeth Garrett-Mayer; Shikhar Mehrotra; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Res       Date:  2016-10-15       Impact factor: 12.701

8.  p53 Hinders CRISPR/Cas9-Mediated Targeted Gene Disruption in Memory CD8 T Cells In Vivo.

Authors:  Samarchith P Kurup; Steven J Moioffer; Lecia L Pewe; John T Harty
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

9.  Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

Authors:  Anirban Banerjee; Krishnamurthy Thyagarajan; Shilpak Chatterjee; Paramita Chakraborty; Pravin Kesarwani; Myroslawa Soloshchenko; Mazen Al-Hommrani; Kristina Andrijauskaite; Kelly Moxley; Harinarayanan Janakiraman; Matthew J Scheffel; Kristi Helke; Kent Armenson; Viswanathan Palanisamy; Mark P Rubinstein; Elizabeth-Garrett Mayer; David J Cole; Chrystal M Paulos; Michael I Nishimura; Shikhar Mehrotra
Journal:  Cancer Res       Date:  2016-07-27       Impact factor: 12.701

10.  Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53.

Authors:  Kyoung Wan Yoon; Sanguine Byun; Eunjeong Kwon; So-Young Hwang; Kiki Chu; Masatsugu Hiraki; Seung-Hee Jo; Astrid Weins; Samy Hakroush; Angelika Cebulla; David B Sykes; Anna Greka; Peter Mundel; David E Fisher; Anna Mandinova; Sam W Lee
Journal:  Science       Date:  2015-07-31       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.